Screener
Inhibrx Biosciences, Inc. INBX Common stock, par value (in dollars per share)
Common stock, par value (in dollars per share) at other companies
Other financials
Where this comes from
Reported directly by Inhibrx Biosciences, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CommonStockParOrStatedValuePerShare.
The source filing: Inhibrx Biosciences, Inc.’s 10-Q, filed May 14, 2026.
- Filed
- May 14, 2026, 4:02 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0002007919-26-000027
| Line item | MARCH 31, 2026 | DECEMBER 31, 2025 |
|---|---|---|
| Commitments and contingencies (Note 6) | ||
| Stockholders’ equity (deficit) | ||
| Preferred stock, $0.0001 par value; 15,000,000 shares authorized as of March 31, 2026 and December 31, 2025; no shares issued or outstanding as of March 31, 2026 and December 31, 2025. | — | — |
| Common stock, $0.0001 par value; 120,000,000 shares authorized as of March 31, 2026 and December 31, 2025; 14,607,286 shares issued and outstanding as of March 31, 2026 and 14,577,609 shares issued and outstanding as of December 31, 2025. | 1 | 1 |
| Additional paid-in-capital | 258,592 | 254,179 |
| Accumulated deficit | (279,628) | (246,187) |
| Total stockholders’ equity (deficit) | (21,035) | 7,993 |
| Total liabilities and stockholders’ equity (deficit) | $183,967 | $146,478 |
Item 1. Financial Statements (unaudited)
FAQ
- What is Inhibrx Biosciences, Inc.'s common stock, par value (in dollars per share)?
- Inhibrx Biosciences, Inc. (INBX) reported common stock, par value (in dollars per share) of $0 in Q1 2026.
- How has Inhibrx Biosciences, Inc.'s common stock, par value (in dollars per share) changed year-over-year?
- Inhibrx Biosciences, Inc.'s common stock, par value (in dollars per share) decreased by 0.0% year-over-year, from $0 to $0.
- What is the long-term trend for Inhibrx Biosciences, Inc.'s common stock, par value (in dollars per share)?
- Over 2 years (2023 to 2025), Inhibrx Biosciences, Inc.'s common stock, par value (in dollars per share) has grown at a 0.0% compound annual growth rate (CAGR), from $0 to $0.
Ask your AI about Inhibrx Biosciences, Inc.'s common stock, par value (in dollars per share).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude